WO2001004335A3 - Human-bovine chimeric respiratory syncytial virus vaccines - Google Patents

Human-bovine chimeric respiratory syncytial virus vaccines Download PDF

Info

Publication number
WO2001004335A3
WO2001004335A3 PCT/US2000/017755 US0017755W WO0104335A3 WO 2001004335 A3 WO2001004335 A3 WO 2001004335A3 US 0017755 W US0017755 W US 0017755W WO 0104335 A3 WO0104335 A3 WO 0104335A3
Authority
WO
WIPO (PCT)
Prior art keywords
rsv
human
genome
bovine
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/017755
Other languages
French (fr)
Other versions
WO2001004335A2 (en
WO2001004335A8 (en
Inventor
Ursula Buchholz
Peter L Collins
Brian R Murphy
Stephen S Whitehead
Christine D Krempl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Priority to JP2001509539A priority Critical patent/JP2003530073A/en
Priority to CA002378552A priority patent/CA2378552A1/en
Priority to MXPA02000220A priority patent/MXPA02000220A/en
Priority to BR0013195-4A priority patent/BR0013195A/en
Priority to EP00941756A priority patent/EP1287152B1/en
Priority to DE60041280T priority patent/DE60041280D1/en
Priority to AU56415/00A priority patent/AU784216B2/en
Priority to IL14744700A priority patent/IL147447A0/en
Publication of WO2001004335A2 publication Critical patent/WO2001004335A2/en
Priority to IL147447A priority patent/IL147447A/en
Anticipated expiration legal-status Critical
Publication of WO2001004335A3 publication Critical patent/WO2001004335A3/en
Publication of WO2001004335A8 publication Critical patent/WO2001004335A8/en
Priority to AU2006202170A priority patent/AU2006202170B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18541—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18543—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Chimeric human-bovine respiratory syncytial virus (RSV) are infectious and attenuated in humans and other mammals and useful in vaccine formulations for eliciting an anti-RSV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric RSV genome or antigenome which includes a partial or complete human or bovine RSV 'background' genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different RSV strain. Chimeric human-bovine RSV of the invention include a partial or complete 'background' RSV genome or antigenome derived from or patterned after a human or bovine RSV strain or subgroup virus combined with one or more heterologous gene(s) or genome segment(s) of a different RSV strain or subgroup virus to form the human-bovine chimeric RSV genome or antigenome. In preferred aspects of the invention, chimeric RSV incorporate a partial or complete bovine RSV background genome or antigenome combined with one or more heterologous gene(s) or genome segment(s) from a human RSV. Genes of interest include any of the NS1, NS2, N, P, M, SH, M2(ORF1), M2(ORF2), L, F or G genes or a genome segment including a protein or portion thereof. A variety of additional mutations and nucleotide modifications are provided within the human-bovine chimeric RSV of the invention to yield desired phenotypic and structural effects.
PCT/US2000/017755 1999-07-09 2000-06-23 Human-bovine chimeric respiratory syncytial virus vaccines Ceased WO2001004335A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2001509539A JP2003530073A (en) 1999-07-09 2000-06-23 Production of an attenuated human-bovine chimeric respiratory syncytial virus vaccine
CA002378552A CA2378552A1 (en) 1999-07-09 2000-06-23 Production of attenuated, human-bovine chimeric respiratory syncytial virus vaccines
MXPA02000220A MXPA02000220A (en) 1999-07-09 2000-06-23 Production of attenuated, human-bovine chimeric respiratory syncytial virus vaccines.
BR0013195-4A BR0013195A (en) 1999-07-09 2000-06-23 Production of attenuated human-bovine chimeric respiratory syncytial virus vaccines
EP00941756A EP1287152B1 (en) 1999-07-09 2000-06-23 Human-bovine chimeric respiratory syncytial virus vaccines
DE60041280T DE60041280D1 (en) 1999-07-09 2000-06-23 CHIMERIC HUMAN CATTLE RESPIRATORY SYNCYTIAL VIRUS VACCINES
IL14744700A IL147447A0 (en) 1999-07-09 2000-06-24 Production of attenuated, human-bovine chimeric respiratory syncytial virus vaccines
AU56415/00A AU784216B2 (en) 1999-07-09 2000-06-24 Production of attenuated, human-bovine chimeric respiratory syncytial virus vaccines
IL147447A IL147447A (en) 1999-07-09 2002-01-03 Immunogenic composition comprising an infectious bovine-human chimeric respiratory syncytial virus and polynucletide molecule comprising the genome of said virus
AU2006202170A AU2006202170B2 (en) 1999-07-09 2006-05-23 Production of attenuated, human-bovine chimeric respiratory syncytial virus vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14313299P 1999-07-09 1999-07-09
US60/143,132 1999-07-09

Publications (3)

Publication Number Publication Date
WO2001004335A2 WO2001004335A2 (en) 2001-01-18
WO2001004335A3 true WO2001004335A3 (en) 2002-12-19
WO2001004335A8 WO2001004335A8 (en) 2003-02-06

Family

ID=22502738

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/017755 Ceased WO2001004335A2 (en) 1999-07-09 2000-06-23 Human-bovine chimeric respiratory syncytial virus vaccines

Country Status (13)

Country Link
US (2) US7829102B2 (en)
EP (1) EP1287152B1 (en)
JP (1) JP2003530073A (en)
KR (1) KR100905450B1 (en)
CN (2) CN101260386A (en)
AT (1) ATE419369T1 (en)
AU (2) AU784216B2 (en)
BR (1) BR0013195A (en)
CA (1) CA2378552A1 (en)
DE (1) DE60041280D1 (en)
IL (2) IL147447A0 (en)
MX (1) MXPA02000220A (en)
WO (1) WO2001004335A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US7201907B1 (en) 1997-05-23 2007-04-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US20030082209A1 (en) 2000-07-05 2003-05-01 Skiadopoulos Mario H. Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7951383B2 (en) 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
US7632508B2 (en) 1997-05-23 2009-12-15 The United States Of America Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7662397B2 (en) 1997-07-15 2010-02-16 The United States Of America As Represented By The Department Of Health And Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
US20040005542A1 (en) 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
IL147436A0 (en) * 1999-07-13 2002-08-14 Us Gov Health & Human Serv Respiratory syncytial viruses expressing immune modulatory molecules
US7820181B2 (en) 2002-09-18 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens
JP2007524372A (en) 2003-02-28 2007-08-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ Recombinant human metapneumovirus and uses thereof
WO2004113517A2 (en) 2003-06-09 2004-12-29 Wyeth IMPROVED METHOD FOR THE RECOVERY OF NON-SEGMENTED, NEGATIVE-STRANDED RNA VIRUSES FROM cDNA
US7588770B2 (en) 2003-12-10 2009-09-15 The Uab Research Foundation Recombinant viruses of the paramyxoviridae family with heterologous envelope glycoproteins
CN101360823A (en) * 2005-11-24 2009-02-04 财团法人阪大微生物病研究会 Recombinant multivalent vaccine
US20100260792A1 (en) * 2007-10-22 2010-10-14 University Of Rochester Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres
US20110189232A1 (en) * 2008-07-01 2011-08-04 The Government Of The United States Of America Represented By The Secretary RECOMBINANT HUMAN PARAINFLUENZA TYPE 1 VIRUSES (HPIV1s) CONTAINING MUTATIONS IN OR DELETION OF THE C PROTEIN ARE ATTENUATED IN AFRICAN GREEN MONKEYS AND IN CILIATED HUMAN AIRWAY EPITHELIAL CELLS AND ARE POTENTIAL VACCINE CANDIDATES FOR HPIV1
BRPI0921424A2 (en) 2008-11-05 2016-01-05 Merck Sharp & Dohme attenuated respiratory syncytial virus, immunogenic composition, nucleic acid molecule, recombinant cell, method for producing a protective immune response in a patient, and use of an immunologically effective amount of one or more of the following: an attenuated rsv, a population of rsv attenuated and an immunogenic composition.
GB201019240D0 (en) 2010-11-15 2010-12-29 Vib Vzw Respiratory syncytical virus vaccine
WO2012085936A2 (en) * 2010-12-20 2012-06-28 Panacea Biotech Ltd Recombinant respiratory syncytial virus plasmids and vaccines
CN102210859B (en) * 2011-05-31 2012-11-21 昆明理工大学 A kind of mycobacterium tuberculosis ESAT-6-F2 fusion protein subunit vaccine and its preparation method
PL3511015T3 (en) 2012-04-13 2021-09-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services GENETICALLY STABLE LIVE ATENUATED RESPIRATORY SYNCITIAL VIRUS AND PRODUCTION
JP2014236748A (en) * 2014-08-26 2014-12-18 一般財団法人阪大微生物病研究会 Recombinant polyvalent vaccine
EP3247388B1 (en) 2015-01-20 2025-09-10 The United States of America, as represented by The Secretary, Department of Health and Human Services Recombinant human/bovine parainfluenza virus 3 (b/hpiv3) expressing a chimeric rsv/bpiv3 f protein and uses thereof
CN110506060B (en) 2017-03-30 2024-05-07 昆士兰大学 Chimeric molecules and their uses
KR20210005090A (en) * 2018-04-23 2021-01-13 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Chimera vector
BR112021006970A2 (en) * 2018-10-12 2021-07-27 Sk Bioscience Co., Ltd. recombinant rsv live vaccine strain and method of producing it
CN110229219B (en) * 2019-06-21 2021-03-30 中国科学院武汉病毒研究所 Preparation method of a novel respiratory syncytial virus vaccine antigen and use thereof
EP4013459B1 (en) 2019-08-16 2025-07-23 Mayo Foundation for Medical Education and Research Chimeric vesiculoviruses and methods of use
CL2020000857A1 (en) * 2020-03-31 2021-11-05 Univ Pontificia Catolica Chile New use of bcg immunogenic formulation expressing a human respiratory syncytial virus protein against bvrs in bovines
EP4496580A4 (en) * 2022-03-22 2025-07-30 Mayo Found Medical Education & Res Morreton viruses and methods of use
CN116676275B (en) * 2023-03-17 2024-06-07 北京赛尔富森生物科技有限公司 A-genotype chimeric mumps virus strain and preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012032A1 (en) * 1995-09-27 1997-04-03 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of infectious respiratory syncytial virus from cloned nucleotide sequences
WO1998002530A1 (en) * 1996-07-15 1998-01-22 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
WO1999015631A1 (en) * 1997-09-26 1999-04-01 Aviron, Inc. Recombinant rsv virus expression systems and vaccines
WO1999024564A1 (en) * 1997-11-10 1999-05-20 University Of Maryland PRODUCTION OF NOVEL BOVINE RESPIRATORY SYNCYTIAL VIRUSES FROM cDNAs

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800078A (en) 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
AU7007491A (en) 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
GB9200117D0 (en) 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Attenuated respiratory syncytial virus vaccine compositions
AU3660893A (en) 1993-01-29 1994-08-15 Med Immune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
DK0702085T4 (en) 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Recombinant infectious non-segmented negative-stranded RNA virus
WO1996010400A1 (en) 1994-09-30 1996-04-11 The Uab Research Foundation Gene therapy vectors and vaccines based on non-segmented negatives stranded rna viruses
US5716821A (en) 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
EP0780475B2 (en) 1995-08-09 2006-07-19 SCHWEIZ. SERUM- & IMPFINSTITUT BERN Process for the production of infectious negative-strand RNA viruses
US6165774A (en) 1995-09-22 2000-12-26 Connaught Laboratories Limited Parainfluenza virus glycoproteins and vaccines
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US6713066B1 (en) 1996-07-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6923971B2 (en) 1995-09-27 2005-08-02 The United States Of America As Represented By The Department Of Health & Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
US5869036A (en) 1995-12-08 1999-02-09 St. Louis University Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine
US6077514A (en) 1996-04-04 2000-06-20 The Regents Of The University Of Michigan Attenuated respiratory syncytial virus
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
DE69842165D1 (en) 1997-05-23 2011-04-21 Us Of America As Represented By The Secretary Of The Dept Of Health And Human Services PREPARATION OF ATTENUATED PARAIN FLUENZA VIRUS VACCINES FROM CLONED NUCLEOTIDE SEQUENCES
DE69837764T2 (en) 1997-07-11 2008-01-31 Yale University, New Haven RHABDOVIRUS WITH GENUINE CHANGED CASE
IL145797A0 (en) 1999-04-13 2002-07-25 Government Of The Us Dept Of H Production of attenuated negative stranded rna virus vaccines from cloned nucleotide sequences
JP2002541785A (en) 1999-04-13 2002-12-10 アメリカ合衆国 Production of an attenuated chimeric respiratory rash virus vaccine from cloned nucleotide sequences
WO2001004321A1 (en) 1999-07-09 2001-01-18 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of m2 orf2
IL147436A0 (en) 1999-07-13 2002-08-14 Us Gov Health & Human Serv Respiratory syncytial viruses expressing immune modulatory molecules
BRPI0112276B8 (en) * 2000-06-23 2021-05-25 The Government Of The Us Secretary Of Department Of Health And Human Services infectious recombinant respiratory syncytial virus (rsv) and isolated polynucleotide containing a partial or complete recombinant resv genome or antigenome

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012032A1 (en) * 1995-09-27 1997-04-03 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of infectious respiratory syncytial virus from cloned nucleotide sequences
WO1998002530A1 (en) * 1996-07-15 1998-01-22 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
WO1999015631A1 (en) * 1997-09-26 1999-04-01 Aviron, Inc. Recombinant rsv virus expression systems and vaccines
WO1999024564A1 (en) * 1997-11-10 1999-05-20 University Of Maryland PRODUCTION OF NOVEL BOVINE RESPIRATORY SYNCYTIAL VIRUSES FROM cDNAs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BUCHHOLZ UJ, GRANZOW H, SCHULDT K, WHITEHEAD SS, MURPHY BR, COLLINS PL.: "Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine.", J VIROL. 2000 FEB;74(3):1187-99., XP000972255 *
BUCHHOLZ, U.J. ET AL.: "Generation of Bovine Respiratory Syncytial Virus (BRSV) from cDNA: BRSV is not essential for virus replication in tissue culture , and the human RSV Leader region acts as a functional BRSV genome promoter", JOURNAL OF VIROLOGY., vol. 73, no. 1, January 1999 (1999-01-01), ICAN SOCIETY FOR MICROBIOLOGY US, pages 251 - 259, XP002154541 *

Also Published As

Publication number Publication date
US20070184069A1 (en) 2007-08-09
CN101260386A (en) 2008-09-10
AU5641500A (en) 2001-01-30
ATE419369T1 (en) 2009-01-15
KR100905450B1 (en) 2009-07-02
CN1402792A (en) 2003-03-12
JP2003530073A (en) 2003-10-14
IL147447A (en) 2010-05-31
EP1287152B1 (en) 2008-12-31
WO2001004335A2 (en) 2001-01-18
AU2006202170B2 (en) 2009-10-08
EP1287152A2 (en) 2003-03-05
US7829102B2 (en) 2010-11-09
US20060057158A1 (en) 2006-03-16
KR20020092343A (en) 2002-12-11
MXPA02000220A (en) 2005-08-16
US7842798B2 (en) 2010-11-30
AU2006202170A1 (en) 2006-06-15
AU784216B2 (en) 2006-02-23
WO2001004335A8 (en) 2003-02-06
IL147447A0 (en) 2002-08-14
CA2378552A1 (en) 2001-01-18
DE60041280D1 (en) 2009-02-12
CN100354425C (en) 2007-12-12
BR0013195A (en) 2002-07-23

Similar Documents

Publication Publication Date Title
WO2001004335A8 (en) Human-bovine chimeric respiratory syncytial virus vaccines
US6790449B2 (en) Methods for producing self-replicating infectious RSV particles comprising recombinant RSV genomes or antigenomes and the N, P, L, and M2 proteins
US5993824A (en) Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
WO2001042445A3 (en) USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS
AU2020203460B2 (en) Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
MXPA01013302A (en) Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines.
US6689367B1 (en) Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US10967014B2 (en) Respiratory syncytial virus with a genomic deficiency complemented in trans
HU229101B1 (en) Dna transfection system for the generation of infectious influenza virus
KR100746979B1 (en) Preparation of Attenuated Chimeric Respiratory Syncitium Virus Vaccine from Cloned Nucleotide Sequence
AU9585298A (en) Recombinant rsv virus expression systems and vaccines
Wertz et al. Approaches to immunization against respiratory syncytial virus
Crowe Jr et al. Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene
Tao et al. A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge
BR0112276A (en) Isolated infectious recombinant respiratory syncytial virus, method for stimulating an individual's immune system to induce protection against rsv, immunogenic composition and isolated polynucleotide molecule
WO2002002605A3 (en) Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
WO2004092207A3 (en) Respiratory syncytial virus (rsv) peptides
WO1998002180A1 (en) Two-step immunization procedure against the pyramyxoviridae family of viruses using attenuated viral strains and subunit protein preparation
WO2025128971A1 (en) Rsv vaccine bearing a polynucleotide which is de-optimised and de-attenuated
EP0859831A1 (en) Production of infectious respiratory syncytial virus from cloned nucleotide sequences
Attenuated Recombinant Respiratory Syncytial Virus
AU5591601A (en) Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 147447

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 56415/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2378552

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/A/2002/000220

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020027000318

Country of ref document: KR

Ref document number: 008101191

Country of ref document: CN

Ref document number: 2000941756

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10030951

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020027000318

Country of ref document: KR

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 03/2001 UNDER (22) REPLACE THE EXISTING DATE BY "20000623"

WWP Wipo information: published in national office

Ref document number: 2000941756

Country of ref document: EP